Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $112.65 (market cap $16.78B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: iShares 3 7 Year Treasury Bond ETF is far larger — about 2.2× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 3 7 Year Treasury Bond ETF for 45 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| IEI | SYRE | |
|---|---|---|
Market Cap | $16.78B | $7.52B |
Volume | 2,469,699 | 1,441,031 |
Sector | Fixed Income | Health |
52-Week High | $120.72 | $108.92 |
52-Week Low | $113.17 | $22.18 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEI is trading at $113.57 with minimal daily movement (+0.08%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. The stock faces resistance at $114 and support at $113. Recent dividend payments of $0.37-$0.38 per share demonstrate shareholder returns, but key valuation metrics (P/E, P/S, P/B) are unavailable for fundamental assessment.
The outlook remains cautious due to the bearish technical setup and lack of fundamental visibility. Bond market volatility highlighted in recent news (Bloomberg, Reuters September 2026) could impact financial sector sentiment. Investment appeal hinges on forthcoming financial disclosures to validate valuation, while current technical resistance near $114 limits near-term upside potential.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
